KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Abbott Laboratories (ABT) Equity Average (2016 - 2025)

Abbott Laboratories' Equity Average history spans 17 years, with the latest figure at $52.0 billion for Q4 2025.

  • For Q4 2025, Equity Average rose 233.57% year-over-year to $52.0 billion; the TTM value through Dec 2025 reached $52.0 billion, up 233.57%, while the annual FY2025 figure was $50.2 billion, 109.73% up from the prior year.
  • Equity Average for Q4 2025 was $52.0 billion at Abbott Laboratories, up from $22.3 billion in the prior quarter.
  • Across five years, Equity Average topped out at $52.0 billion in Q4 2025 and bottomed at -$12.3 billion in Q4 2022.
  • The 5-year median for Equity Average is $700.5 million (2023), against an average of $6.4 billion.
  • The largest annual shift saw Equity Average plummeted 5623.08% in 2021 before it skyrocketed 477.76% in 2024.
  • A 5-year view of Equity Average shows it stood at $6.7 billion in 2021, then crashed by 283.16% to -$12.3 billion in 2022, then surged by 66.54% to -$4.1 billion in 2023, then surged by 477.76% to $15.6 billion in 2024, then surged by 233.57% to $52.0 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Equity Average are $52.0 billion (Q4 2025), $22.3 billion (Q3 2025), and -$3.2 billion (Q2 2025).